20/20 Biolabs Inc. (AIDX) Stock Analysis & Investment Frameworks
20/20 Biolabs Inc. (AIDX) stock analysis on Invetso. Review 20/20 Biolabs Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
20/20 Biolabs Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Care Facilities
- Country: US
20/20 Biolabs Inc. Key Financial Metrics
- Market Cap: $3.33M
- Revenue: $2.05M
- ROE: -387.27%
- ROIC: -116.89%
- Dividend Yield: N/A
About 20/20 Biolabs Inc.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
20/20 Biolabs Inc. Investment Frameworks
Invetso analyzes 20/20 Biolabs Inc. (AIDX) across the following frameworks:
- 20/20 Biolabs Inc. 10Y Growth Potential
- 20/20 Biolabs Inc. Scenario Analysis
- 20/20 Biolabs Inc. Risks & Opportunities
- 20/20 Biolabs Inc. Economic Moat
- 20/20 Biolabs Inc. Business Model
- 20/20 Biolabs Inc. Management
- 20/20 Biolabs Inc. SWOT Analysis
- 20/20 Biolabs Inc. Porter's 5 Forces
- 20/20 Biolabs Inc. PESTLE Analysis
- 20/20 Biolabs Inc. ESG Analysis